Session 7: Integrating Immunotherapy for NSCLC

2:30pm – 3:30pm

Program Overview

The emergence of checkpoint inhibitors (CTLA4, PD1, PD-L1) has reawakened an interest in immunotherapy to treat various malignancies. New agents have rapidly been approved for use in melanoma, bladder cancer, renal cell, lung cancer and other malignancies. These agents have a unique toxicity profile requiring careful clinical assessment, rapid intervention and aggressive management of side effects.

This session will provide a general overview of immunotherapy in cancer treatment, with a special focus on non-small cell lung cancer (NSCLC). Challenges of biomarker interpretation and use will also be addressed.

Clinical data regarding three currently FDA approved checkpoint inhibitors will be presented and discussed.

Learning Objectives

  • Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
  • Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with lung cancer
  • Discuss current recommendations for diagnostic testing for lung cancer to facilitate treatment selection
  • Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of lung cancer patients with attention to cost/benefit and toxicity considerations
  • Evaluate communication strategies and resources to increase patient access and engagement

CME/CPE/CNE Information

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hour (0.10 CEUs) of continuing education credit (UAN: 0418-9999-17-7205-L04-P).

This is an application-based activity.

Nurses

1.0 ANCC Contact hours provided by Postgraduate Institute for Medicine

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

A statement of credit will be issued only upon receipt of a completed activity evaluation.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CME/CPE/CNE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A certificate will be provided after submission of a completed evaluation form.

There is no fee associated with this program.

Special Services

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc).  Please contact MEDX Conference Planning prior to the live event at medx@mededexchange.com.

Jointly provided by The Potomac Center for Medical Education, Postgraduate Institute of Medicine, and Rockpointe Oncology

                  

This activity is supported by independent educational grants from AstraZeneca, Lilly, Novartis Pharmaceutical Corporation and Sanofi Genzyme.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Faculty Information


Gary I. Cohen, MD
Associate Professor, Oncology, Johns Hopkins
Director Emeritus, Berman Cancer Institute Greater
Baltimore Medical Center, Baltimore, MD